Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic
(PK) profiles of Chiglitazar following administration of a single oral dose in subjects with
varying degrees of hepatic impairment compared to subjects with normal hepatic function.